UNIVERSITY of York

This is a repository copy of *Targeting deficiencies in the TLR5 mediated vaginal response* to treat female recurrent urinary tract infection.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/119009/</u>

Version: Accepted Version

Article:

Ali, Ased SM, Mowbray, Catherine, Lanz, Marcelo et al. (12 more authors) (2017) Targeting deficiencies in the TLR5 mediated vaginal response to treat female recurrent urinary tract infection. Scientific Reports. ISSN 2045-2322

https://doi.org/10.1038/s41598-017-10445-4

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

1	
2	Targeting Deficiencies in the TLR5 Mediated Vaginal Response to Treat Female Recurrent
3	Urinary Tract Infection.
4	
5	Authors: Ased SM All ^{1,2a} , Catherine Mowbray ¹ , Marcelo Lanz ¹ , Anna Stanton ¹ , Samantha Bowen ³ ,
6	Claire L Varley ⁴ , Paul Hilton ² , Karen Brown ² , Wendy Robson ² , Jennifer Southgate ⁴ , Phillip Aldridge ¹ ,
7	Alison Tyson-Capper ¹ , Soman Abraham ³ , [*] Robert S Pickard ^{1,2*} , Judith Hall ^{1*} ,
8	*Judith Hall and Robert S Pickard contributed equally to this work as senior supervising authors.
9	Institutions:
10	1. Institutes of Cell & Molecular Biosciences and Cellular Medicine, Newcastle University, UK
11	2. Newcastle upon Tyne Hospitals NHS Trust, UK
12	3. Duke University, NC, USA
13	4. Jack Birch Unit, University of York, UK
14	5. ^a Present address Mid Yorkshire Hospitals, Aberford Rd, Wakefield, UK
15	
16	Corresponding Author:
17	Dr Judith Hall, Institute for Cell & Molecular Biosciences, Faculty Medical Sciences, Newcastle
18	University
19	
20	Telephone: +44 (0) 1912088346
21	Email: Judith.Hall@ncl.ac.uk
22	
23	
24	Summary: The identification of the host defence peptides as target effectors in the innate defence of
25	the uro-genital tract creates new translational possibilities for immunomodulatory therapies,
26	specifically vaginal therapies to treat women suffering from rUTI, particularly those carrying the
27	TLR5_C1174T SNP.
28	
29	
50	
31	
32	
33	
34	
25	
ээ Эс	
30	
37	
38	

39 Urinary tract infections (UTIs) are a microbial disease reported worldwide. Women are particularly 40 susceptible with many suffering debilitating recurrent (r) infections. Treatment is by antibiotics, but 41 such therapy is linked to antibiotic resistance and re-infection. This study explored the innate 42 protective mechanisms of the urogenital tract with the aim of boosting such defences therapeutically.

43 Modelling UTIs *in vitro*, human vaginal and bladder epithelial cells were challenged with 44 uropathogenic *Escherichia coli* (CFT073) and microbial PAMPs including flagellin, LPS and 45 peptidoglycan. Flagellin functioning via the TLR5/NFκB pathway was identified as the key UPEC 46 virulence factor causing a significant increase (P<0.05) in the production of the host-defence peptide 47 (HDP), BD2. BD2-depleted urine samples from bladder infected mice supported increased UPEC 48 growth, strengthening the significance of the HDPs in protecting the urogenital tissues from infection.

Clinically, vaginal-douche BD2 concentrations were reduced (p<0.05) in women suffering rUTIs, compared to age-matched healthy controls with concentrations further decreased (p<0.05) in a TLR5^{392Stop} SNP rUTI subgroup. Topical vaginal estrogen treatment increased (p<0.001) BD2 concentrations in all women, including those carrying the SNP. These data identify therapeutic and antibiotic sparing roles for vaginal immunomodulatory agents that specifically target HDP induction, facilitate bacterial killing and disrupt the UPEC infection cycle.</p>

55

56 Introduction

57 Urinary tract infections (UTI), linked to Escherichia coli infecting the bladder are one of the most 58 prevalent microbial diseases, accounting for over eight million health-care visits yearly in the United States ¹. Females are particularly susceptible ² and of those women affected 5%, rising to 13% in 59 those aged over 60, ^{3,4} will suffer from debilitating recurrent infections (rUTI). These infections not only 60 impact on a person's quality of life, but are also associated with escalating healthcare costs ¹. In a 61 62 number of cases the recurrent infections can be linked to an abnormality of the urinary tract ⁵, but a 63 major characteristic of the disease is the poorly-defined relationship between the host 64 genotype/phenotype and the main pathogen, uropathogenic E. coli (UPEC).

In healthy individuals, the lower urinary tract is maintained free of pathogens through the functioning of host defences that include the pH and ionic composition of urine, which in conjunction with the flushing action of urine are detrimental to bacterial adherence and growth. Evidence also suggests

68 that these physical factors are supported by host innate, rather than adaptive, immune defence 69 mechanisms with the high rates of UTI linked to the bladder's inability to mount an antibody 70 response⁶. Innate elements protecting the lower urinary tract include the activities of either 71 constitutively or induced host defence molecules. Antimicrobial agents such as uromodulin facilitate 72 bacterial removal by binding UPEC directly, while others, including lactoferrin and neutrophil 73 gelatinase-associated lipocalin-2, function by sequestering iron to restrict bacterial survival and 74 growth⁷. Small cationic peptides, synthesised by epithelia and neutrophils, and including the 75 defensins, cathelicidin, and ribonucleases, are also part of the urinary tract innate defences⁸. These 76 molecules, in addition to their intrinsic bacterial killing properties, fight infection through their 77 immunomodulatory properties that promote increased cytokine production and neutrophil infiltration ⁹. 78 However, the actual roles of such peptides in protecting the urogenital tract from infection remain 79 contentious. Studies involving mice deficient in the antimicrobial peptides Defb1 (analogous to human 80 Beta-Defensin-1) and cathelin-related antimicrobial peptide (analogous to the cathelicidin hCAP-18) 81 report conflicting results, with the absence of peptides associated with either increased, reduced or no differences in UTI susceptibility ¹⁰⁻¹³. 82

83 Epithelial cells recognise potential pathogens through receptors including the Toll-like receptors 84 (TLRs). Once activated, the TLRs induce a rapid response that results in microbial killing either 85 directly through the synthesis and activities of antimicrobial agents or indirectly through chemokines, 86 and the attraction of neutrophils and macrophages. Studies focussed on UPEC infection of the 87 murine urinary tract suggest that TLR4 activation, linked to the detection of microbial 88 lipopolysaccharide and/or FimH, the adhesin portion of the Type 1 fimbriae that secures UPEC 89 attachment to urothelial cells, can trigger host innate antimicrobial defences ¹⁴. Following urothelial 90 cell invasion, TLR4 is further implicated in the expulsion of UPEC and reinfection of the urinary tract, via an exocytic pathway linked to cellular cAMP¹⁵. However, *in vitro* data using proliferating and 91 92 differentiated normal urothelial cells favours TLR5 signalling mechanisms predominating in the human 93 bladder ¹⁶. In support, murine studies have also demonstrated bacterial motility and TLR5 to be a key 94 factors in UPEC pathogenicity, with wild-type flagellated UPEC shown to out-compete non-flagellated 95 *fliC* mutants and maximum expression of flagellar genes coinciding with UPEC ascent into the ureters and kidneys ^{17,18}. Clinically, patient susceptibility to UTI links to polymorphisms of both receptor genes 96 97 with a TLR4 A896G polymorphism related to rUTI protection, but a TLR5 C1174T SNP linked to an increased susceptibility to repeated infections ^{19,20}. 98

99 Current management strategies for rUTI sufferers are generally prophylactic involving long-term low 100 dose antibiotics. In reality such strategies provide limited long-term benefit and encourage bacterial 101 resistance that further complicates patient management. The treatment also conflicts with the current public health challenges of managing and reducing antibiotic overuse ^{21,22}. Increasing concerns 102 103 relating to the overuse of antibiotics has stimulated interest in alternative therapies including vaccine 104 development and identification of agents able to boost endogenous innate defences of the urogenital 105 tract⁸. In females the initiating event of an UTI involves colonisation of the vaginal mucosa by UPEC originating, it is presumed, from the gut microbiota²³, with UTI caused by the subsequent urethral 106 migration and attachment of these bacteria to the urothelium ²⁴. 107

We show here that not only does deficiency in the vaginal host antimicrobial defences link to recurrent UTIs, but also that vaginal innate defences can be enhanced through topical immune boosting agents. We propose that such agents can be utilised to disrupt the UPEC infection cycle and hence offer an effective antibiotic-sparing approach to the treatment of rUTIs.

112 Results

113 E.coli and Flagellin induce a TLR5-Mediated BD2 Response in Urogenital Epithelia

114 Immortalised vaginal (VK2 E6/E7) and bladder cancer (RT4) cells modelling the urogenital epithelial 115 tissues were challenged with a heat-inactivated suspension of the motile flagellated UPEC strain 116 CFT073 and E.coli flagellin. Expression of genes DEFB1, DEFB4, DEFB103A, LCN2, SLPI, hCAP-18 117 and DEF5A encoding the host defence molecules BD1, BD2, BD3, Lipocalin2, secretory leukocyte 118 protease inhibitor (SLPI), cathelicidin and HD5 were assessed using end-point PCR. While these data 119 suggested DEFB1 and DEFB4 gene expression to be upregulated (Fig 1a and Supplementary S1a-120 d), gRT-PCR analyses identified only a significant increase in DEFB4 gene expression (Figs 1b & Fig 121 **S2)** with these observations accompanied by a significant increase in BD2 peptide following CFT073 122 (P<0.05) and flagellin (P<0.001) challenge (Fig 1c). These data were substantiated using primary 123 human ureteric urothelial and vaginal epithelial cells (Fig 1d & e). Hence we selected BD2, an 124 inducible bacterial killing molecule and immunomodulatory agent with reported potency in inhibiting UTI progression ²⁵ as our key target in exploring and devising strategies to boost the UT innate 125 126 defences.

127 Challenging VK2 E6/E7 and RT4 cells with flagellated (motile) and non-flagellated (non-motile)
 128 *Escherichia coli* indicated that the signalling mechanism controlling BD2 production in the urogenital

129 tissues was TLR5 mediated and linked to flagellin (Fig 1f). This was further indicated by a reduction in 130 DEFB4 transcript expression in flagellin challenged vaginal VK2 E6/E7 cells following siRNA silencing 131 of TLR5 gene expression (Fig 1g). In support decreased BD2 concentrations were also detected in 132 the media bathing the vaginal cells similarly challenged with flagellin, but in which TLR5 had been 133 blocked using antibody (Fig 1h). The use of RT4 bladder cells engineered to contain a NFκB-134 luciferase reporter also indicated the NFkB signalling pathway to be involved with a four hour flagellin 135 challenge linked to a significant 44.8 fold increase in luciferase activity (P<0.001) (Fig 1i). In 136 comparison only slight induction of NFxB activity was observed at four hours following either 137 peptidoglycan (3.1 fold) or lipopolysaccharide (LPS) challenges (6.7 fold) with maximal responses at 138 16 hours of 6.2 and 10.7 fold respectively (Fig 1i). However, LPS challenges of up to 24 hours in vitro 139 did not induce *DEFB4* expression (FigS3). These data identified TLR5/NFκB/BD2 as a key signalling 140 pathway in the innate response of the urogenital epithelia to a flagellated UPEC infection.

141 Deficiency of BD2 Orthologue (DefB4) in Mice Increases Susceptibility to UTI

142 To verify this pathway and the significance of host defence peptides including BD2 in vivo, C57BL/6J 143 WT and TIr5^{-/-} knockout mice bladders were inoculated with either buffer (PBS), E.coli derived flagellin 144 (5µg) or CFT073 (10⁸) and the murine bladder and vaginal tissues examined for *DefB4* gene expression. The *DefB4* gene is the mouse orthologue of the human *DEFB4* gene ²⁶. C57BL/6J WT 145 146 mice showed a significant increase in bladder *DefB4* transcript expression (P<0.05) in response to the 147 flagellin challenge (Fig 2a), while significant changes in both bladder and vaginal expression (P<0.05) 148 were associated with the bacterial (CFT073) infection (Fig 2a, b). No renal DefB4 transcript 149 expression was identified (data not shown) and no bacteria were recovered from the kidneys (Fig 2c).

The bladder and vaginal tissues of similarly challenged $Tlr5^{-}$ mice showed no significant induction of *DefB4* transcript expression (**Fig 2a, b**). At six hours post challenge the bladder bacterial counts of these mice were also significantly higher than those recorded in the C57BL/6J WT mice (**Fig 2c**). Additionally bacteria were recovered from the kidneys of the $Tlr5^{-}$ mice indicating the increased susceptibility of their urinary tracts to an ascending UTI (**Fig 2c**). These *in vivo* data supported the significance of the urogenital epithelial TLR5/BD2 host defence peptide (HDP) signalling response in the immediate protection of the lower and upper urinary tract from UPEC infection.

157

158

159 Biological Relevance of BD2 in the Innate Response of the Uro-genital Tract

160 To address the biological relevance of host defence peptides in the innate defence of the urogenital 161 tissues the antimicrobial potencies of an array of agents including BD2, LCN and SLPI (7.5 to 250 162 nM) were compared using a time-kill assay approach and CFT073 as the target bacterium. Using peptide concentrations mimicking those at the epithelial surface^{27,28} these assay data suggested the 163 164 induced BD2 peptide to possess significant antimicrobial potency against the CFT073 strain (Fig 3a). 165 Immuno-depletion of BD2 from the wild-type mouse urine samples collected following challenge with 166 CFT073 and flagellin was also associated with increased CFT073 growth (Fig 3b). These data 167 provided direct evidence that a urogenital deficiency of host defence peptide links to the increased 168 risk of UTI.

169 Women with rUTI and TLR5_C1174T SNP show Reduced BD2

170 To examine the clinical significance of host defence peptides in defending against rUTIs we focused 171 on DEF4B expression and BD2 synthesis in vaginal biopsies, vaginal secretions (douche) and urine 172 samples from 86 women. Forty-eight women had a history of rUTIs, including 14 with a symptomatic 173 E.coli infection at time of sampling and 38 were age-matched controls. Analyses of the vaginal 174 biopsies indicated that those women suffering rUTIs showed significantly lower DEF4B transcript 175 expression (p<0.05) compared to their respective controls (Fig 4a). The vaginal douche 176 measurements also supported these data with the mean BD2 concentration being significantly 177 reduced (P<0.05) in the rUTI cohort (25.3±3.2 pg/ml) compared to the control group (38.9±5.5 pg/ml) 178 (Fig 4b). Stratification of these vaginal douche data also showed that the mean BD2 concentrations of 179 the pre and postmenopausal rUTI cohorts were significantly decreased (p<0.05) compared to their 180 respective controls (Fig 4c). Furthermore, the mean BD2 concentration of the postmenopausal rUTI 181 group was significantly decreased (p<0.001) compared to that of the premenopausal rUTI cohort.

TLR5 gene expression data suggested no significant differences between vaginal expression in the control and rUTI cohorts, and expression was elevated significantly (P<0.05) during active infections (**Fig 4d**). These data suggested that the observed reductions in BD2 were related to cellular signalling events linked to and/or downstream of TLR5. To explore this further we sequenced the TLR5 genes of the patient and control cohorts. Sequencing identified a sub-group of six women (7%), all contained within the rUTI group, who carried the TLR5_C1174T single nucleotide polymorphism (SNP). Also known as TLR5^{392Stop}, this polymorphism is a heterozygous variant present in 5-10% of the population encoding a stop-codon, which is reported to increase the susceptibility of those affected to flagellated
 infections ^{29,30}. Vaginal douche measurements also supported HDP concentrations being significantly
 lower (P<0.01) in this group compared to the no SNP rUTI cohort (Fig 4b).

192 Of the fourteen women with an active UTI during our sample collections, nine carried the wild-type TLR5 gene and five the TLR5^{392Stop} SNP. Analyses of urines and vaginal washings of these women 193 194 during their active infections showed that the SNP cohort had significantly lower mean BD2 195 concentrations in both urine (P<0.05) and vaginal douche (P<0.001) samples compared to those of 196 the no SNP group (Fig 4e). Furthermore, analysing the urine BD2 concentrations of the TLR5^{392Stop} 197 SNP cohort during periods of infection and quiescence showed no significant differences (Fig 4f), 198 confirming the inability of the urogenital tissues of these SNP patients to respond to infection. In 199 contrast the urine BD2 concentrations of the no SNP rUTI patients were elevated (P<0.01) in 200 response to infection (Fig 4f). However, further analyses showed that the BD2 concentrations of the 201 no SNP rUTI patients measured during an active UTI were actually very similar to those of the control 202 pre-menopausal group (Fig 4g). These data suggested that the vaginal BD2 responses in the no SNP 203 rUTI patients were considerably compromised, which increased their susceptibility to recurrent 204 infections. The diminished host BD2 response of the no SNP rUTI group implicated host signalling 205 defects linked to and/or downstream of TLR5.

206 To demonstrate that the rUTIs suffered by the SNP patients were due to host-susceptibility rather 207 than bacterial virulence factors, *E.coli* were isolated from the urine samples of three of the SNP 208 patients and used to challenge the stably transfected RT4-NFKB luciferase reporter cells. Significant 209 increases in NFkB-reporter activity comparable to flagellin (250ng/ml) were recorded following challenges with each of the UPEC strains (Fig 4h). These data verified that the genetic TLR5^{392Stop} 210 211 polymorphism played a key role in predisposing these women to repeated UTIs. Modelling the 212 polymorphism experimentally by TLR5 antibody blocking of the RT4-NF κ B luciferase reporter cells, 213 prior to bacterial challenges, reduced NFkB reporter activity (Fig 4i) and diminished the epithelial 214 effector IL-8 and BD2 responses (Fig 4j, k). Consistent with the bladder response (Fig 4k) and 215 patient data a reduction in BD2 was observed in similarly challenged vaginal cells (Fig 4S). These 216 data provided further evidence that in the urogenital tract the epithelial host TLR5-NFκB-HDP 217 signalling pathway functions in helping to protect from UTIs and if compromised, the loss of such defences, can expose the tissues to infection. 218

219 Deficient BD2 Responses can be Enhanced Therapeutically *In Vitro* and Clinically

220 For all rUTI patients, including those carrying the TLR5 SNP, topical agents that boost the urogenital 221 defences, including BD2 synthesis, may provide additional and/or alternative therapies to antibiotics. 222 Vaginal estrogen supplements can be used to reduce UTI risk in post-menopausal women suffering rUTIs, but the mechanisms of action are not fully understood ³¹⁻³³. When VK2 E6/E7 vaginal cells 223 224 were supplemented with 4nM estrogen for 7 days and then challenged with flagellin (50ng/ml) DEF4B 225 transcript expression and BD2 synthesis were significantly (P<0.01) potentiated (Fig 5a, b). These in 226 vitro data suggest that the steroid hormone, in addition to its roles in reproduction, functions in 227 augmenting the innate immune defences of the urogenital tract. When examined clinically, the 228 vaginal BD2 concentrations of post-menopausal women suffering rUTIs, but prescribed topical vaginal 229 estrogen (Vagifem 10mcg twice weekly), for a minimum of six weeks were significantly increased 230 (P<0.001), compared to those treated using other therapies including antibiotic prophylaxis and/or 231 advice (Fig 5c, d). These vaginal douche data were supported by vaginal biopsies taken from 232 estrogen-treated women that showed immunoreactivity for BD2 (Fig 5e). Together these data provide 233 compelling evidence that estrogen can enhance the host vaginal epithelial defences through the 234 increased synthesis of host defence molecules and help protect from rUTIs. The fact that the BD2 235 vaginal douche concentrations of the rUTI TLR5 SNP patients were augmented in response to topical 236 vaginal estrogen treatment (Fig 5f), lends support to the use of immune-boosting vaginal therapies to 237 help treat rUTIs.

We propose therefore that the TLR5-NFκB-host defence effector pathway is a significant innate defence mechanism helping to protect the urogenital tract against rUTI. We propose that for women carrying the TLR5 SNP and hence genetically predisposed to rUTI, as well as post-menopausal women, this pathway be exploited clinically. We argue that the use of topical immune modulating therapies that activate and/or enhance the vaginal innate defences will help prevent bacterial colonisation and ascension into the urinary tract (**Fig 5g**).

244 Discussion

UTI is one of the most prevalent microbial diseases worldwide. It is characterised by high recurrence rates amongst sufferers and by the marked, and increasing multi-drug resistance profiles of uropathogenic bacteria, a consequence of the mainstay therapy being limited to repeated or prophylactic antibiotic treatments ^{34,35}. Key challenges to science and medicine are to reduce recurrence rates and improve patient outcomes through new therapeutic options that curtail antibioticusage.

251 To address this our studies focussed on both bacterial virulence factors and the host urogenital defences. In support of previous reports^{16,18} our *in vitro* and murine data indicated that flagellated 252 253 E.coli through TLR5 activation play a key role in the pathology of UTI. These data were further 254 strengthened by our clinical findings, which showed that all patients carrying the TLR5 C1174T SNP, 255 encoding a stop mutation linked to increased susceptibility to flagellated bacteria²⁰, suffered from 256 recurrent UTIs. The fact that the in vitro, murine and clinical study data were all characterised by the 257 reduced production of host defence molecules, including bacterial killing peptides and chemokines, 258 provided a mechanistic explanation to link a TLR5 deficiency to repeated infections of the bladder. 259 Furthermore this immunodeficiency impacted similarly on the TLR5 signalling pathway of the vaginal 260 tissues. In view of this we propose that the resultant reduction in innate effector molecules facilitates 261 the repeated colonisation of the vaginal mucosa by gut E. coli, which drives the persistent bladder 262 infections. This mechanism also explains why antibiotic therapy can never cure women carrying the TLR5^{392Stop} SNP and in fact why repeated treatments only exacerbate the condition through selecting 263 264 for antibiotic resistance. Hence as a first step we propose that women suffering uncomplicated rUTI 265 should be tested for the SNP to further inform their clinical management. However, herein lies the 266 next problem as there are few clinical alternatives to treating rUTIs other than advice and antibiotics.

267 Topical estrogen treatment is an option in reducing UPEC colonisation of the vaginal tissues and 268 helping to protect against repeated infections. Our clinical data, which showed elevated vaginal BD2 269 concentrations in patients prescribed estrogen treatment corroborated a previous report where 270 estrogen therapy enhanced the bladder innate response and strengthened the integrity of the 271 urothelium ³². Our premise that estrogen functions synergistically to boost the urogenital innate 272 defences was further supported by our observation of a significant reduction in the urine and vaginal 273 douche BD2 concentrations of postmenopausal patients suffering rUTI, but carrying wild-type TLR5. 274 The report that vaginal estrogen is also associated with increased Lactobacilli growth, which impacts on the survivability of uropathogens ³⁶, further supports its use as a rUTI therapy. Yet, despite its 275 276 potential, vaginal estrogen is clinically acceptable only in post-menopausal women and due to concerns including endometrial hyperplasis³⁷ is only recommended for limited periods. However, 277 278 other potential agents for therapeutic consideration-include hyaluronic acid and chondroitin sulphate,

279 whose intravesical use have been linked to decreased UTI recurrence and *in vitro* to host defence

280 peptide stimulation, including increased defensin synthesis ³⁸⁻⁴⁰.

281 Our vaginal therapy option to help treat rUTI sufferers carrying the TLR5 SNP (Fig 5g) is based on the 282 premise that recurrence links to infections that are propagated through bacteria originating in the gutfaecal material ascending the urethra into the bladder^{23,41,42}. However, recurrent infections can also be 283 284 explained using the intracellular bacterial community/quiescent intracellular reservoir (IBC/QIR) model 285 established through studies in mice⁴³. This model relies on UPEC ascending the urethra, invading the 286 bladder epithelium and forming either IBCs that contain metabolically-active bacteria capable of 287 infecting adjacent cells or non-replicating quiescent intracellular reservoirs. Following a stimulus, 288 possibly months after the initial infection and potentially involving urothelial turnover involving actin 289 rearrangements, these latent bacteria emerge to initiate a new acute infection. However, while the 290 IBC/QIR model has been demonstrated in multiple mouse backgrounds⁴⁴ there is limited evidence to 291 support its functioning in humans^{45,46}. Furthermore, the infection model does not fit well with data that links vaginal treatments to reduced UTI incidence^{31,33} 292

293 The answer to developing rUTI therapies applicable for all groups of women lies in understanding the 294 disease pathology in relation to both the host response and bacterial virulence. To date, studies 295 investigating UTIs and potential new UTI treatments have focussed largely on the virulence factors used by uropathogens at the primary site of infection, the bladder ⁴³. While such information is not 296 297 generally taken into account in clinical decisions involving antibiotics, it has informed potential 298 treatment strategies including vaccination. However, the use of vaccines to treat rUTIs remains 299 tentative with whole pili immunogens proving ineffective and other methods focussed on UPEC toxins, 300 siderophores and the FimC-FimH complex, either providing no protection or reducing, but not totally inhibiting bladder colonisation ^{47,48}. Oral therapeutics called mannosides, which function as FimH 301 302 anatagonists and reduce bacterial attachment at the bladder tissues show strong potential with the 303 efficacy of a new class, the C-mannosides, demonstrated in vivo using animal models of UTI ^{49,50}. 304 Recently the FimH antagonist M4284 has been shown to reduce UPEC colonisation of the mouse gut 305 without impacting on the gut microbiota, and hence if developed therapeutically, could reduce UTIs and rUTIs⁵¹. Deliberately establishing asymptomatic bacteruria in UTI-prone patients through the use 306 of non-adhering *E.coli*, has also been reported to be relatively successful in reducing UTI episodes ⁵². 307 308 However, from our knowledge and understanding of the host innate defences we also advocate the 309 development and use of topical vaginal treatments that function, either by mimicking the action of

- estrogen or through novel signalling pathways, to boost the endogenous innate defences of the vaginal tissues and reduce vaginal *E.coli* colonisation (**Fig 5g**). We propose that such treatments, by interrupting the UPEC infection cycle, will offer an additional, but simple antibiotic-sparing therapeutic approach to the treatment of patients suffering rUTIs including those carrying the TLR5^{392Stop} SNP.
- 314
- 315

316 Methods

317 Cell Culture

The RT4 urothelial cell line (ATCC HTB-2) ⁵³ was maintained without antibiotics in 25mM HEPES (4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid) modified RPMI 1640 medium supplemented with 2 mM glutamine and 10% fetal bovine serum (Sigma, Dorset, UK). VK2 E6/E7 cells (ATCC CRL-2616) ⁵⁴ were maintained without antibiotics in keratinocyte serum-free medium (GIBCO, Paisley, UK) containing 0.4mM calcium with 0.1 ng/ml human recombinant Epidermal Growth Factor (EGF) and 0.05 mg/ml bovine pituitary extract supplements. Normal human urothelial cells were isolated, expanded and maintained in culture as previously described ⁵⁵.

325 Cell Challenge Studies

RT4 and VK2 E6/E7 cells were seeded at 10^4 cells/well into 30 mm, six well plates and cultured to confluency at 37°C in 5% CO₂. Prior to challenge, cell monolayers were washed in phosphate buffered saline (PBS) and incubated for 24h in fresh medium.

NU14⁵⁶, NCTC 10418 (ATCC 10536), K12⁵⁷ and CFT073 ⁵⁸ bacterial cultures were tested for motility 329 330 as described previously ⁵⁹. Bacterial cultures were prepared for use in cell challenge experiments as 331 follows: Fifty µl of a 5ml log phase culture was used to inoculate a further 5 ml of medium and cultured 332 again to log-phase (3 h). Twenty µl of this culture was re-suspended in 980 µl PBS to give a working 333 suspension and 20 µl of this (approximately 5x10⁴ colony forming units (CFU)) used to inoculate each 334 well of eukaryote cells for the time required. Dead bacteria were produced by incubating live bacterial 335 stock solution for 30 minutes at 65 °C and confirmed by overnight agar plating. For bacterial 336 component challenges, each well of eukaryote cells was inoculated with 20 µL of either LPS, Peptidoglycan (Invivogen, San Diego, California, USA) or E. coli flagellin⁶⁰. For BD2 enhancement 337 338 studies cells were supplemented with 4nM cyclodextrin encapsulated 17β-oestradiol dissolved in 339 water (Sigma) or 15nM (2-hydroxypropyl)- β -cyclodextrin for up to seven days prior to challenge. Once

- the cells reached 80% confluency the cell culture medium was removed, the cells were washed with
- 341 PBS and incubated a further 24 hours in medium supplemented with 15nM cyclodextrin only. At each
- 342 appropriate challenge time points the medium was removed from the wells and stored at -20°C for
- 343 ELISA and the cells subjected to RNA extraction.
- The time-kill antimicrobial assays using recombinant peptides, BD2 (Preprotech), LCN2 (Biovision),
 and SLPI (RD systems) were adapted from the technique used previously ⁶¹.

346 NFkB Reporter Measurements

RT4 cells stably transfected with a NFκB luciferase reporter ⁶² and maintained under G418 selection (Sigma, UK) at 0.5mg/ml were seeded onto 30 mm diameter, six well plates at a density of 10⁵ cells/well and cultured until 90% confluent. Following challenge with either PBS, bacteria or bacterial components, the cells were lysed in RLB (Promega, Southampton, UK) for 16 hours at -80 °C and following the addition of luciferin (Promega), luminescence was measured using a FluoStar Omega microplate reader (BMG Labtech, Ortenberg, Germany). The results were presented as fold increase over the control PBS challenge.

Activation of TLR-5 was inhibited by incubating cells with up to 5 µg/ml of mouse monoclonal TLR-5 antibody (maba2-htlr5, Invivogen, San Diego, USA) or IgG (5µg/ml) 2 hours prior to bacterial or flagellin challenge.

357 End-point, Quantitative RT-PCR and siRNA analyses

Extraction of RNA from either cultured cells or the human tissue samples was performed using TRIzol® reagent following the manufacturer's instructions (Invitrogen) and all RNA samples were stored in RNAsin[™] (Promega) at -80 °C. cDNA preparation and transcript abundance, measured by either end-point or quantitative RT-PCR, was as previously described ⁶¹. Quality of extracted RNA was assessed using a Bioanalyzer 2100 (Agilent Technologies, Berkshire, UK) to ensure a minimum RIN of 8.0 for quantitative real time PCR (RT-qPCR) analyses of the *in vitro* samples and 7.0 for biopsy samples. Primers and annealing temperatures are presented in Table 1.

Transfection of VK2 cells with TLR5 siRNA (s14199:ThermoFisher) was performed using Viromer Green (Lipocalyx) following the manufacturer's protocol. The 48h knockdown was followed by a 24h flagellin challenge.

368

369 Bacterial Growth Measurements

370 The immunosorbent experiments utilised urines collected from both flagellin and CFT073 challenged 371 C57BL/6 wild-type mice. Urine samples were added to BD2 or Avian BD9 antibody (Cambridge 372 Research Biochemicals, Cleveland, U.K.) coated ELISA plates (Leinco Technologies) and following a 373 2h incubation the supernatants recovered and stored at -20 °C. Supernatants (100 µl/well) were used 374 in bacterial growth experiments performed in 96 well microtitre plates and data analysed in relation to 375 lag time extension ⁶³. For bacterial growth, over-night cultures of CFT073 were inoculated into Luria 376 broth, grown to mid-log phase (OD₆₀₀=0.4), diluted to 10⁴ cells/ml and aliquoted into wells of 96-well 377 microtitre plates containing control or biological samples. The plates were incubated for 16 h in a 378 Fluostar Omega plate reader set at 37°C, shaken at 200rpm every 20 min and the bacterial OD₆₀₀ 379 measured every 20 min.

380 Human Beta-Defensin 2 (BD2) and Interleukin 8 (IL-8) Measurements

Human BD2 was quantitated in clinical and cell culture samples using a Human BD2 ELISA
Development Kit (Leinco Technologies, St Louis, Missouri, USA). IL-8 concentrations were analysed
using the BD optEIA IL-8 ELISA kit (BD Bioscience, Franklin Lakes, USA).

384 Mice Experiments

C57BL/6J wild-type and B6.129S1-T/r5^{tm/Fly}/J (T/r5^{-/-} knockout) female mice (obtained from Jackson 385 386 Laboratories, Bar Harbor, ME.) were bred to between 6 and 8 weeks of age at the Duke University 387 Medical Center animal care facility. E. coli CFT073 and E.coli flagellin were used for all murine 388 infections. CFT073 cultures were inoculated from frozen stock into Luria broth [Becton Dickinson and 389 Company (BD), Franklin Lakes, NJ] and grown overnight at 37°C. Optical density (OD) was 390 determined and cultures were washed, and diluted in PBS. Bladder infections were performed as described previously ⁶. Essentially mice were anesthetized, catheterized with polyethylene tubing 391 (inner diameter: 0.28 mm) (BD), and 50 µl of PBS (control) or PBS containing either 10⁸ bacteria or 5 392 393 µg E.coli flagellin instilled from a 1 ml tuberculin syringe with a 30G1/2 needle. Mice were euthanized 394 by CO₂ asphyxiation and whole tissues (vaginas, bladders and kidneys) isolated for transcript 395 analyses and bacterial CFU quantification. All animal experiments were approved by the Duke 396 University IACUC and Division of Laboratory Animal Resources, and performed in accordance with 397 relevant guidelines and regulations.

398 Human Subjects

399 The study was approved by the County Durham & Tees Valley 1 NHS Research Ethics Committee 400 (09/H0905/15) and Newcastle upon Tyne Hospitals NHS Trust (ID 4841). Written informed consent 401 was obtained from all participants and all methods were performed in accordance with relevant 402 guidelines and regulations. Women with structurally-normal urinary tracts and consenting to provide 403 biopsies, samples of blood, urine and vaginal washings were recruited from the Urology and Uro-404 gynaecology departments of Newcastle upon Tyne Hospitals NHS Trust from July 2009 to February 405 2011. Controls were recruited from women attending for investigation of haematuria or other non-406 infection related uro-gynaecological assessment; rUTI sufferers were women who had suffered either 407 at least two episodes per year for two years or three episodes in the previous year. Other inclusion 408 criteria required subjects to be aged 18 years or older; pre-menopausal or at least six months 409 post-menopause; no antibiotic therapy within four weeks of recruitment. Pre-investigation sample size 410 calculations based on previous reported urinary AMP concentrations indicated that 18 women in each 411 of the four groups (72 in total) would give 80% chance of detecting a difference at 5% significance 412 level. The women were stratified according to menopausal status to create four groups: 19 Pre-413 menopausal controls (median age 35: range 18-46); 31 Pre-menopausal cases (rUTI sufferers) 414 (median age 31: range 18-41) for which there were 26 complete analyses; 19 Post-menopausal 415 controls (median age 58: range 42-76); 29 Post-menopausal cases (rUTI sufferers) (median age 60: 416 range 40-75) for which there were 22 complete analyses. Clinical histories of rUTI and control 417 subjects are presented in Table 2.

418 **Patient samples**

419 Biopsies from the first 2-3 cm of the vagina and posterior bladder wall were obtained during 420 cystoscopy. Following cystoscopy, the first vaginal washing or douche was collected using the 421 'Summer's Eve Cleansing Douche' (Fleet Laboratories, Lynchburg, Virginia, USA) according to the 422 manufacturer's instructions. Each subject was given the necessary instructions and containers to 423 collect an overnight urine specimen (approximately 600-800ml) and a further vaginal douche 6-8 424 weeks later. Pre-menopausal subjects were requested to collect the douche at the mid-point of their 425 menstrual cycle. Of the subjects that gave two douche samples, all were post-menopausal; nine were 426 rUTI sufferers prescribed vaginal estrogen (Vagifem twice weekly 10mcg) and 12 were rUTI sufferers 427 given treatments including antibiotic prophylaxis and/or advice (one did not complete).

428 Targeted TLR5 Sequencing

429 Blood samples taken from each subject were processed for genomic DNA (gDNA) extraction using 430 the GeneCatcher[™] gDNA 3–10 mL Blood Kit (Invitrogen, Paisley, UK). PCR amplification of the TLR5^{392Stop} containing region of the TLR5 gene was carried out on 100ng of gDNA using Novagen 431 432 Kod Host start DNA Polymerase (Merck Millipore, Darmstadt, Germany) and the TLR5 Primer pair 433 GGTAGCCTACATTGATTTGC; (forward primer. reverse primer, 434 GAGAATCTGGAGATGAGGTACCCG). A 10µL aliquot of the 461 bp product was used for 435 sequencing (Genevision, Newcastle upon Tyne, UK). Sequencing data was provided in AB1 format 436 and data analyses performed using the freeware FinchTV trace viewing software (Geospiza, Seattle, 437 USA).

438 Immunohistochemistry

Vaginal samples for immunohistochemistry were fixed in formalin overnight before being transferred to 70% ethanol for long term storage or paraffin embedding. Sections of 5-µm thickness were mounted on microscope slides and following microwave-heat mediated antigen retrieval were stained with anti-beta 2 Defensin primary antibody (Abcam, ab63982)1/1000 (1 X PBS), overnight at 4°C, followed by one hour at room temperature with polyclonal goat anti-rabbit Immunoglobulins/HRP 1/3000 (DAKO). Images were taken using a Nikon Eclipse Ti, coupled to a Photometrics Coolsnap HQ CCD camera and Nikon Plan Fluor 100x/1.30 ph3 DL lens.

446

447 Statistical Analyses

All statistical analyses were performed out using the Prism 5 Software package (GraphPad Software Inc, La Jolla, California, USA). Significance of data with two groups was determined by unpaired twotailed Student's t test; for more than two groups a two–way analyses of variance followed by Tukey's multiple comparison or Bonferroni post-tests, as appropriate, was used. For comparison of the first and second douche data, a paired two-tailed test was utilised.

References

- 1 Foxman, B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infectious disease clinics of North America* **28**, 1-13, doi:10.1016/j.idc.2013.09.003 (2014).
- 2 Schappert, S. M. & Rechtsteiner, E. A. Ambulatory medical care utilization estimates for 2006. *National health statistics reports*, 1-29 (2008).
- 3 Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. *The American journal of medicine* **113 Suppl 1A**, 5S-13S (2002).
- Kucheria, R., Dasgupta, P., Sacks, S. H., Khan, M. S. & Sheerin, N. S. Urinary tract infections: new insights into a common problem. *Postgraduate medical journal* 81, 83-86, doi:10.1136/pgmj.2004.023036 (2005).
- 5 Geerlings, S. E. Clinical Presentations and Epidemiology of Urinary Tract Infections. *Microbiology spectrum* **4**, doi:10.1128/microbiolspec.UTI-0002-2012 (2016).
- 6 Chan, C. Y., St John, A. L. & Abraham, S. N. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. *Immunity* **38**, 349-359, doi:10.1016/j.immuni.2012.10.019 (2013).
- 7 Ali, A. S., Townes, C. L., Hall, J. & Pickard, R. S. Maintaining a sterile urinary tract: the role of antimicrobial peptides. *The Journal of urology* **182**, 21-28, doi:10.1016/j.juro.2009.02.124 (2009).
- 8 Abraham, S. N. & Miao, Y. The nature of immune responses to urinary tract infections. *Nature reviews. Immunology* **15**, 655-663, doi:10.1038/nri3887 (2015).
- 9 Hancock, R. E., Haney, E. F. & Gill, E. E. The immunology of host defence peptides: beyond antimicrobial activity. *Nature reviews. Immunology* **16**, 321-334, doi:10.1038/nri.2016.29 (2016).
- 10 Chromek, M. *et al.* The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. *Nature medicine* **12**, 636-641, doi:10.1038/nm1407 (2006).
- 11 Valore, E. V. *et al.* Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. *The Journal of clinical investigation* **101**, 1633-1642, doi:10.1172/JCl1861 (1998).
- 12 Becknell, B. *et al.* Expression and antimicrobial function of beta-defensin 1 in the lower urinary tract. *PloS one* **8**, e77714, doi:10.1371/journal.pone.0077714 (2013).
- 13 Danka, E. S. & Hunstad, D. A. Cathelicidin augments epithelial receptivity and pathogenesis in experimental Escherichia coli cystitis. *The Journal of infectious diseases* **211**, 1164-1173, doi:10.1093/infdis/jiu577 (2015).
- 14 Ashkar, A. A., Mossman, K. L., Coombes, B. K., Gyles, C. L. & Mackenzie, R. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. *PLoS pathogens* 4, e1000233, doi:10.1371/journal.ppat.1000233 (2008).
- 15 Song, J. *et al.* TLR4-mediated expulsion of bacteria from infected bladder epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 14966-14971, doi:10.1073/pnas.0900527106 (2009).
- 16 Smith, N. J. *et al.* Toll-like receptor responses of normal human urothelial cells to bacterial flagellin and lipopolysaccharide. *The Journal of urology* **186**, 1084-1092, doi:10.1016/j.juro.2011.04.112 (2011).
- 17 Lane, M. C., Alteri, C. J., Smith, S. N. & Mobley, H. L. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 16669-16674, doi:10.1073/pnas.0607898104 (2007).
- 18 Andersen-Nissen, E. *et al.* Cutting edge: TIr5-/- mice are more susceptible to Escherichia coli urinary tract infection. *Journal of immunology* **178**, 4717-4720 (2007).
- 19 Hawn, T. R. *et al.* Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women. *PloS one* **4**, e8300, doi:10.1371/journal.pone.0008300 (2009).

- 20 Hawn, T. R. *et al.* Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. *PloS one* **4**, e5990, doi:10.1371/journal.pone.0005990 (2009).
- 21 Paphitou, N. I. Antimicrobial resistance: action to combat the rising microbial challenges. International journal of antimicrobial agents **42 Suppl**, S25-28, doi:10.1016/j.ijantimicag.2013.04.007 (2013).
- 22 Silverman, J. A., Schreiber, H. L. t., Hooton, T. M. & Hultgren, S. J. From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections. *Current urology reports* **14**, 448-456, doi:10.1007/s11934-013-0354-5 (2013).
- Nienhouse, V. *et al.* Interplay between bladder microbiota and urinary antimicrobial peptides: mechanisms for human urinary tract infection risk and symptom severity. *PloS one* 9, e114185, doi:10.1371/journal.pone.0114185 (2014).
- 24 Stamey, T. A. & Sexton, C. C. The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. *The Journal of urology* **113**, 214-217 (1975).
- 25 Zhao, J., Wang, Z., Chen, X., Wang, J. & Li, J. Effects of intravesical liposome-mediated human beta-defensin-2 gene transfection in a mouse urinary tract infection model. *Microbiology and immunology* **55**, 217-223, doi:10.1111/j.1348-0421.2011.00315.x (2011).
- Rohrl, J., Yang, D., Oppenheim, J. J. & Hehlgans, T. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. *Journal of immunology* 184, 6688-6694, doi:10.4049/jimmunol.0903984 (2010).
- Ganz, T. Defensins: antimicrobial peptides of innate immunity. *Nature reviews. Immunology* **3**, 710-720, doi:10.1038/nri1180 (2003).
- 28 Shi, J. *et al.* Porcine epithelial beta-defensin 1 is expressed in the dorsal tongue at antimicrobial concentrations. *Infection and immunity* **67**, 3121-3127 (1999).
- 29 Hawn, T. R. *et al.* A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. *The Journal of experimental medicine* **198**, 1563-1572, doi:10.1084/jem.20031220 (2003).
- 30 Wlasiuk, G., Khan, S., Switzer, W. M. & Nachman, M. W. A history of recurrent positive selection at the toll-like receptor 5 in primates. *Molecular biology and evolution* **26**, 937-949, doi:10.1093/molbev/msp018 (2009).
- 31 Beerepoot, M. A., Geerlings, S. E., van Haarst, E. P., van Charante, N. M. & ter Riet, G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. *The Journal of urology* **190**, 1981-1989, doi:10.1016/j.juro.2013.04.142 (2013).
- 32 Luthje, P. *et al.* Estrogen supports urothelial defense mechanisms. *Science translational medicine* **5**, 190ra180, doi:10.1126/scitranslmed.3005574 (2013).
- ³³ Perrotta, C., Aznar, M., Mejia, R., Albert, X. & Ng, C. W. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *The Cochrane database of systematic reviews*, CD005131, doi:10.1002/14651858.CD005131.pub2 (2008).
- 34 Gupta, K., Hooton, T. M., Wobbe, C. L. & Stamm, W. E. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. *International journal of antimicrobial agents* **11**, 305-308 (1999).
- 35 Gupta, K., Scholes, D. & Stamm, W. E. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. *Jama* **281**, 736-738 (1999).
- 36 Klebanoff, S. J., Hillier, S. L., Eschenbach, D. A. & Waltersdorph, A. M. Control of the microbial flora of the vagina by H2O2-generating lactobacilli. *The Journal of infectious diseases* **164**, 94-100 (1991).
- 37 Hill, D. A. & Hill, S. R. Counseling patients about hormone therapy and alternatives for menopausal symptoms. *American family physician* **82**, 801-807 (2010).
- 38 De Vita, D., Antell, H. & Giordano, S. Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent bacterial cystitis in adult women: a meta-analysis. *International urogynecology journal* 24, 545-552, doi:10.1007/s00192-012-1957-y (2013).

- 39 Dusio, G. F. *et al.* Stimulation of TLRs by LMW-HA induces self-defense mechanisms in vaginal epithelium. *Immunology and cell biology* **89**, 630-639, doi:10.1038/icb.2010.140 (2011).
- 40 Ciani, O. *et al.* Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. *BMJ open* **6**, e009669, doi:10.1136/bmjopen-2015-009669 (2016).
- 41 Cass, A. S. & Ireland, G. W. Antibacterial perineal washing for prevention of recurrent urinary tract infections. *Urology* **25**, 492-494 (1985).
- 42 Handley, M. A., Reingold, A. L., Shiboski, S. & Padian, N. S. Incidence of acute urinary tract infection in young women and use of male condoms with and without nonoxynol-9 spermicides. *Epidemiology* **13**, 431-436 (2002).
- 43 Hannan, T. J. *et al.* Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. *FEMS microbiology reviews* **36**, 616-648, doi:10.1111/j.1574-6976.2012.00339.x (2012).
- Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nature reviews. Microbiology* 13, 269-284, doi:10.1038/nrmicro3432 (2015).
- 45 Robino, L. *et al.* Intracellular bacteria in the pathogenesis of Escherichia coli urinary tract infection in children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **59**, e158-164, doi:10.1093/cid/ciu634 (2014).
- 46 Rosen, D. A., Hooton, T. M., Stamm, W. E., Humphrey, P. A. & Hultgren, S. J. Detection of intracellular bacterial communities in human urinary tract infection. *PLoS medicine* **4**, e329, doi:10.1371/journal.pmed.0040329 (2007).
- 47 Savar, N. S. *et al.* In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. *Journal of biotechnology* **175**, 31-37, doi:10.1016/j.jbiotec.2014.01.037 (2014).
- 48 Brumbaugh, A. R., Smith, S. N. & Mobley, H. L. Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. *Infection and immunity* **81**, 3309-3316, doi:10.1128/IAI.00470-13 (2013).
- 49 Klein, T. *et al.* FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. *Journal of medicinal chemistry* **53**, 8627-8641, doi:10.1021/jm101011y (2010).
- 50 Mydock-McGrane, L. *et al.* Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. *Journal of medicinal chemistry*, doi:10.1021/acs.jmedchem.6b00948 (2016).
- 51 Spaulding, C. N. *et al.* Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. *Nature*, doi:10.1038/nature22972 (2017).
- 52 Wullt, B. & Svanborg, C. Deliberate Establishment of Asymptomatic Bacteriuria-A Novel Strategy to Prevent Recurrent UTI. *Pathogens* **5**, doi:10.3390/pathogens5030052 (2016).
- 53 Rigby, C. C. & Franks, L. M. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. *British journal of cancer* **24**, 746-754 (1970).
- 54 Fichorova, R. N., Rheinwald, J. G. & Anderson, D. J. Generation of papillomavirusimmortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. *Biology of reproduction* **57**, 847-855 (1997).
- 55 Hutton, K. A., Trejdosiewicz, L. K., Thomas, D. F. & Southgate, J. Urothelial tissue culture for bladder reconstruction: an experimental study. *The Journal of urology* **150**, 721-725 (1993).
- 56 Hultgren, S. J., Schwan, W. R., Schaeffer, A. J. & Duncan, J. L. Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli. *Infection and immunity* **54**, 613-620 (1986).

- 57 Bachmann, B. J. Pedigrees of some mutant strains of Escherichia coli K-12. *Bacteriological reviews* **36**, 525-557 (1972).
- 58 Welch, R. A. *et al.* Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. *Proceedings of the National Academy of Sciences of the United States of America* **99**, 17020-17024, doi:10.1073/pnas.252529799 (2002).
- 59 Aldridge, P., Paul, R., Goymer, P., Rainey, P. & Jenal, U. Role of the GGDEF regulator PleD in polar development of Caulobacter crescentus. *Molecular microbiology* **47**, 1695-1708 (2003).
- 60 Smith, K. D. *et al.* Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. *Nature immunology* **4**, 1247-1253, doi:10.1038/ni1011 (2003).
- 61 Townes, C. L., Ali, A., Robson, W., Pickard, R. & Hall, J. Tolerance of bacteriuria after urinary diversion is linked to antimicrobial peptide activity. *Urology* **77**, 509 e501-508, doi:10.1016/j.urology.2010.08.019 (2011).
- 62 Gong, G., Meplan, C., Gautrey, H., Hall, J. & Hesketh, J. E. Differential effects of selenium and knock-down of glutathione peroxidases on TNFalpha and flagellin inflammatory responses in gut epithelial cells. *Genes & nutrition* **7**, 167-178, doi:10.1007/s12263-011-0256-4 (2012).
- 63 Li, B., Qiu, Y., Shi, H. & Yin, H. The importance of lag time extension in determining bacterial resistance to antibiotics. *The Analyst* **141**, 3059-3067, doi:10.1039/c5an02649k (2016).

Acknowledgements: AA was supported through a Wellcome Trust Clinical Training Fellowship; ML was supported by a Newcastle University William Harker Studentship; AS is supported by a MRC PhD Studentship; we gratefully acknowledge funding from Wellbeing of Woman ref RG1357. JS is funded by York Against Cancer.

Author Contributions: AA performed in vitro studies, recruited patients, analysed patient & mouse samples, collated project data and wrote first draft of manuscript; ML and PA prepared *E.coli* flagella material; ML established RT4 reporter cell line and contributed to the *in vitro* bladder studies; AS performed primary vaginal cell studies and in vitro estrogen studies; SB and SA performed mouse challenge experiments; CLV & JS performed primary human urothelial cell studies and JS contributed to final manuscript; WR, PH & KB were involved in patient recruitment and tissue collection; ATC performed IHC analyses: AA and CM performed patient sample analyses; JH, RSP, PH & ATC supervised the project and contributed to the final manuscript.

Additional Information: There are no competing financial interests.

Figure 1: VK2 E6/E7 and RT4 DEFB4 and BD2 responses to UPEC and flagellin challenges.

End point PCR panels of host defence peptide gene expression in VK2 E6/E7 and RT4 cells following 24hr challenge with PBS (control), flagellin (250ng/ml) or UPEC (10⁵) (**1a**). Full length gels are shown in Supplementary File 1 (S1a-d). DEFB4 transcript expression in VK2 E6/E7 and RT4 cells following challenges with flagellin (250ng/ml) and heat-killed flagellated (NCTC10418) or non-flagellated (NU14) E.coli (10°) (N=3, n=9) (1b). BD2 concentrations measured in VK2 E6/E7 and RT4 cell media following 24 hour challenges with flagellin (250ng/ml) and heat-killed CFT073 (10⁵) (N=3, n=6) (1c). BD2 peptide concentrations of primary ureteric urothelial cells challenged with E.coli flagellin (250ng/ml) for 24 hours (N=3, n=6) (1d). DEFB4 transcript expression, presented as relative expression, of primary vaginal epithelial cells challenged with E.coli flagellin (50ng/ml) for 24 hours (N=6) (1e). E.coli swarming motility on LB agar media; BD2 peptide concentrations measured in VK2 E6/E7 and RT4 cell media following 24 hour challenges with flagellin (250ng/ml) and heat-killed bacteria (10°) (N=3, n=6) (1f). DEFB4 transcript expression of VK2 E6/E7 cells transfected with either negative siRNA or TLR5 siRNA and challenged for 24 hours with flagellin (50ng/ml) (N=3) (1g). BD2 peptide concentrations of VK2 E6/E7 cells incubated with TLR5 blocking antibody (1-5ug/ml) or IgG (5ug/ml) and challenged 24 hours with flagellin (250ng/ml) (N=3) (1h). Fold change in NFκBluciferase activity in RT4 cells challenged with 250ng/ml flagellin (FLG) for 2-8 hours, peptidoglycan (PG) (10 μ g/ml) for up to 16 hours and Lipopolysaccharide (LPS) (10 μ g/ml) for up to 16 hours (N=3, <mark>n=6 (FLG), n=9 (PG & LPS))</mark> (**1i**). All data presented as mean ± SEM, * P<0.05, ** P<0.01, *** P<0.001.

Figure 2: *DefB4* expression in mouse urogenital tissues following UPEC and flagellin challenge

DefB4 mRNA expression in wild type C57BL6 and *Tlr5^{-/-}* mice bladders following 6h challenge with either flagellin (5µg) or CFT073 (10⁸) (N=3) (**2a**). Vaginal *DefB4* mRNA expression in wild type C57BL6 and *Tlr5^{-/-}* mice following 6h challenge with either flagellin (5µg) or CFT073 (10⁸) (N=3) (**2b**). *E. coli* colonisation of the bladders and kidneys of wild type C57BL6 and *Tlr5^{-/-}* mice following 6h challenge (N=3) (**2c**). All data presented as mean ± SEM, * P<0.05, ** P<0.01.

Figure 3: Effects of host defence peptides on CFT073 growth

Time-kill data showing CFT073 survival following two hour incubation with host defence peptides BD2 (30 and 300ng/ml: 7.5nM and 75nM), LCN2 (300 ng/ml: 13nm)) and SLPI (300 and 3000ng/ml: 25 and 250nM) (N=4). Bacterial growth values >100% link to peptide concentrations not associated with bacterial killing suggesting amino acids associated with peptide degradation, either natural or bacterial protease activity, are used by the bacteria as a growth source (**3a**). CFT073 (10⁴) growth times in wild type mice urines depleted of DefB4 (controls: no depletion and Avian defensin antibody-specific depletion) (**3b**). All data presented as mean \pm SEM, * P<0.05, *** P<0.001.

Figure 4: *DEFB4* and *TLR5* mRNA expression, and BD2 responses in control and rUTI patient samples

DEFB4 mRNA expression, presented as relative expression (4a) and BD2 peptide concentrations (4b) in vaginal biopsies from control (N=38) and rUTI patients (N=48). Vaginal douche data stratified to show BD2 peptide concentrations of premenopausal (Pre-M) control subjects (N=19), premenopausal rUTI patients (N=26), postmenopausal (Post-M) control subjects (N=19) and postmenopausal rUTI patients (N=22) (4c). *TLR5* mRNA expression, presented as relative expression, in vaginal biopsies from control subjects, patients with rUTI and rUTI at time of an active infection (4d). Urine BD2 concentrations of the rUTI No SNP (N=8) and TLR5^{392Stop} SNP patients (N=5) and vaginal douche BD2 peptide concentrations N=9 (No SNP) and N=5 (SNP) during periods of active infection (4e). Matched urine BD2 concentrations of rUTI non SNP (N=8) and TLR5^{392Stop} SNP patients (N=5) analysed during periods of infection and non-infection (4f). Vaginal douche BD2 peptide concentrations of rUTI non SNP (N=8) and TLR5^{392Stop} SNP patients (N=5) analysed during periods of infection and non-infection (4f). Vaginal douche BD2 peptide concentrations of rUTI non SNP (N=8) and TLR5^{392Stop} SNP patients (N=5) analysed during periods of infection and non-infection (4f). Vaginal douche BD2 peptide concentrations of rUTI non SNP (N=8) and TLR5^{392Stop} SNP patients (N=5) analysed during periods of infection and non-infection (4f). Vaginal douche BD2 peptide concentrations of rUTI non SNP (N=8) and TLR5^{392Stop} SNP patients (N=5) analysed during periods of infection and non-infection (4f). Vaginal douche BD2 peptide concentrations of rUTI non SNP (N=8) and TLR5^{392Stop} SNP patients (N=5) analysed during periods of infection and non-infection (4f). Vaginal douche BD2 peptide concentrations of no SNP rUTI patients measured during an acute infection alongside vaginal douche BD2 concentrations of the non-infected pre-menopausal control subjects (4g).

NFκB-luciferase activity (fold change) in RT4 cells following 2 to 24 hour challenges with heat killed UPEC (5x10⁴) isolated from the urines of three rUTI SNP patients during an acute infection (**4h**). NFκB-luciferase activity (fold change) in RT4 cells incubated in presence or absence of TLR5 blocking antibody (5ug/ml) or IgG (5ug/ml) following 24 hour challenge with flagellin (250ng/ml) or heat killed UPEC isolated from each of the three SNP patients (**4i**). IL-8 concentrations (pg/ml) in media of RT4 cells incubated in presence or absence of TLR5 blocking antibody (5ug/ml) and challenged for 24 hours with flagellin (250ng/ml) and bacteria isolated from each of the three SNP

patients (**4j**). BD2 concentrations (pg/ml) in media of RT4 bladder cells incubated in presence or absence of TLR5 blocking antibody (5ug/ml) and challenged for 24 hours with either flagellin (250ng/ml) or bacteria isolated from each of the three SNP patients (**4k**). N=2, n=6 and all data presented as mean \pm SEM, * P<0.05, ** P<0.01, *** P<0.001.

Figure 5: Effects of estrogen treatment on BD2 responses in vitro and rUTI patients

VK2 E6/E7 cell *DEFB4* mRNA expression following estrogen (4nM) seven day pretreatment and 24h challenge with either cyclodextrin (15nM), flagellin (50ng/ml), or flagellin (50ng/ml) and estrogen (4nM) N=3 (**5a**). BD2 peptide concentrations measured in the VK2 E6/E7 cell media following estrogen (4nM) seven day pretreatment and either 24h or 48h challenge with either cyclodextrin (15nM), estrogen (4nM), flagellin (50ng/ml) or flagellin and estrogen (N=3) (**5b**). Vaginal douche BD2 peptide concentrations of rUTI patients before and after 6-8 weeks of treatment with antibiotic prophylaxis and/or advice (N=12) (**5c**), or 6 to 8 weeks treatment with vaginal estrogen (Vagifem, 10mcg, twice weekly) (N=9) (**5d**). Staining of vaginal tissue from estrogen treated (+E) and control subjects for immunoreactive BD2 (**5e**). Vaginal douche BD2 peptide concentrations of rUTI TLR5 SNP patients before and after treatment (6 to 8 weeks) with vaginal estrogen (N=3) or antibiotic prophylaxis (N=1) (**5f**). All data presented as mean ± SEM, ** P<0.01, *** P<0.001.

Schematic illustrating (i) how an inherited or acquired reduction in the vaginal host innate defences can facilitate an UPEC infection of the urogenital tract and (ii) how vaginal treatments enhancing the host innate defences can help prevent this (**5g**). **1**. Uropathogenic *E.coli* (UPEC) • originating from bowel migrate from rectum towards vagina; **2**. Inherited or acquired reduction in innate defences including HDP and chemokines facilitates increased vaginal and peri-urethral colonisation by UPEC; **3**. Urethral ascent of UPEC from peri-urethral and vaginal regions to bladder; **4**. Bladder infection; **5**. Vaginal topical agent stimulates host innate defences and UPEC destroyed preventing vaginal colonisation; **6**/**7**. Urethra and bladder protected from UPEC infection.

Gene	Primer Sequence	Primer Type	Tm (°C)
DEFB1	Reverse: <u>cgcc</u> GGTAGGAAGTTCTCATGGcG Forward: GTCAGCTCAGCCTCCAAAGGA	Probes Master	60
Defb4	Forward: GTGAAGCTCCCAGCCATCAG Reverse: GATTGCGTATCTTTGGACACC	SYBR Green I Master	58
DEFB4	SA Biosciences commercial primer	SYBR Green I Master	60
DEFA5	Forward: GCCATCCTTGCTGCCATTC Reverse: GATTTCACACACCCCCGGAGA	SYBR Green I Master	58
hCAP-18	Forward: cgctGACGGGCTGGTGAAGcG Reverse: CCCAGCAGGGCAAATCTCTT	Probes Master	55
TLR5	Forward: CAGAGACTGGTGTTCAAGGAC Reverse: GTGTCCAGGTGTTTGAGCA	SYBR Green I Master	54
GAPDH	Primer Design commercial primer (House-keeping reference gene)	SYBR Green I Master	60
ATP5B	Primer Design commercial primer (House-keeping reference gene)	SYBR Green I Master	60
Mouse β -actin	Forward: TGAGAGGGAAATCGTGCGTGACAT Reverse: ACCGCTCATTGACGATAGTGATGA	SYBR Green I Master	60

Table 1: Primer sequences

	Control		rUTI	
	Pre-menopause	Post-menopause	Pre-menopause	Post-menopause
Numbers Recruited	19	19	31	29
Median Age (Range)	35 (18-46)	58 (42-76)	31 (18-41)	60(40-75)
Prescribed vaginal estrogen previously	1	2	0	0
Taking vitamins	4	3	4	4
Taking cranberry-juice	5	5	16	15
On oral contraception	6	0	4	0
Had HRT	0	4	0	9

Table 2: Clinical History









